Sangamo Therapeutics Bolsa (NASDAQ: SGMO)

Sangamo Therapeutics (NASDAQ:SGMO) Bolsa

SANGAMO THERAPEUTICS INC

Sangamo Therapeutics

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Movers_Stocks

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADPT

CXAI

ENTO

HRTG

IIIN

LION

LSAK

MLNK

MULN

OLMA

RNAC

SGMO

SHCO

SLSR

Sangamo Therapeutics se dispara tras anunciar un acuerdo exclusivo con Eli Lilly sobre tecnología genética patentada. ¿Qué implica esto?

Acciones de Sangamo Therapeutics (SGMO) se disparan un 40%; Aquí están 20 acciones que se mueven en premercado

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Earnings

NMTC

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: AMS, GES, NMTC, SLP y SGMO.

5 acciones en el foco este viernes: AMS, GES, NMTC, SLP y SGMO

Nvidia, Moderna, Lucid, Dominari Holdings, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Equities

FIVE

TSLA

El mercado bursátil estadounidense se desplomó; descubre qué acciones sufrieron más y por qué cayeron tan fuerte.

RH, Five Below, Sangamo, Bank Of America, Tesla: 5 acciones que están en el radar de los inversores

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics Inc

Barclays analyst Gena Wang maintains Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Overweight and lowers the price target from $9 to $5.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $5

<h3>Gainers</h3>
<ul>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) stock increased by 173.1% to $14.23 during Tuesday's regular session. The market value of their outstanding shares is at $15.9 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares increased by 40.75% to $1.03. The market value of their outstanding shares is at $53.2 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 38.01% to $1.67. The market value of their outstanding shares is at $4.9 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) stock moved upwards by 33.33% to $1.76. The market value of their outstanding shares is at $273.0 million. The company's, Q1 earnings came out today. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) stock moved upwards by 27.6% to $1.41. The market value of their outstanding shares is at $53.2 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) stock moved upwards by 27.57% to $1.94. The company's market cap stands at $46.1 million. The company's, Q4 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 91.4% to $0.03 during Tuesday's regular session. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares declined by 64.03% to $4.83. The market value of their outstanding shares is at $228.9 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 38.48% to $0.08. The company's market cap stands at $2.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock decreased by 38.31% to $290.0. The company's market cap stands at $3.7 billion. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock fell 36.51% to $0.47. The market value of their outstanding shares is at $106.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock decreased by 25.95% to $49.31. The market value of their outstanding shares is at $6.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APYX

AXDX

CELU

CNSP

HALO

HCWB

HUMA

PLRZ

ZYBT

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 90.1% to $2.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $6.7 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares increased by 25.15% to $0.19. The market value of their outstanding shares is at $4.7 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares moved upwards by 23.11% to $0.9. The market value of their outstanding shares is at $46.5 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) shares moved upwards by 21.22% to $14.05. The company's market cap stands at $381.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) shares moved upwards by 11.22% to $4.26. The market value of their outstanding shares is at $201.1 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock rose 10.49% to $2.21. The market value of their outstanding shares is at $3.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock declined by 91.8% to $0.03 during Tuesday's pre-market session. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock decreased by 36.8% to $0.47. The market value of their outstanding shares is at $106.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 21.63% to $0.11. The company's market cap stands at $2.6 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares declined by 19.73% to $0.14. The market value of their outstanding shares is at $3.9 million. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) stock fell 16.67% to $0.85. The market value of their outstanding shares is at $98.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares decreased by 16.59% to $0.35. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARCT

CHRS

GCTK

KLTO

RDHL

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

WIIM

Sangamo Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.

U.S. stock futures fell on Tuesday after a stellar rally on Monday. Futures of major benchmark indices were trading lower in premarket.
Tech, consumer discretionary, and communication services led Monday&#8217;s rally as stocks surged on the<a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling"> tariff truce</a> with China. 
President Donald Trump <a href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80">signed an executive order</a> Monday, seeking to slash U.S. drug prices, fulfilling a social media pledge to achieve cuts of at least 59%. 
Meanwhile, the 10-year Treasury bond yielded 4.45% and the two-year bond was at 3.98%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 91.8% likelihood of the Federal Reserve keeping the current interest rates unchanged in its June meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.20%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.44%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.54%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.25%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Tuesday. The SPY was down 0.42% to $580.57, while the QQQ declined 0.50% to $505.29, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Information technology, consumer discretionary, and communication services sectors saw the biggest gains on Monday. The Dow Jones index soared over 1,100 points as the U.S. and China agreed to a <a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">90-day tariff truce</a>, effective May 14. 
This, along with the Trump administration&#8217;s progress to further formal trade talks amid growing economic pressures, fueled the market optimism.
However, this positive Monday followed a down week for major U.S. indices, with the S&amp;P 500, Nasdaq, and Dow all closing lower on Friday.
In stock-specific news, NRG Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) reported strong first-quarter results, while Kindly MD Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares skyrocketed following a Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) treasury strategy merger.
Meanwhile, utility stocks moved against the broader market trend, closing lower.
After Monday, all the indices were out of the correction zone. The S&amp;P 500 index was down 4.93% from its record high of 6,147.43 points, scaled on Feb. 19. Dow Jones was 5.91% lower than its 52-week high of 45,073.63 points, and Nasdaq 100 was 6.09% lower than its previous high of 22,222.61 points.
The Dow Jones index declined 119 points or 0.29% to 41,249.38, whereas the S&amp;P 500 index fell 0.071% to 5,659.91. Nasdaq Composite ended 0.004% higher at 17,928.92, and the small-cap gauge, Russell 2000, dropped 0.16% to 2,023.07.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>4.35%</td>
<td>18,708.34</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>3.26%</td>
<td>5,844.19</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>2.81%</td>
<td>42,410.10</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>3.42%</td>
<td>2,092.20</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Ryan Detrick from Carson Research highlighted in an X post that more than 55% of the S&amp;P 500 components made a new 20-day high on Monday.
According to the historical data presented by him, the S&amp;P 500 index ended 16.3% higher on average following days with such fresh 20-day highs. Out of the 30 times this has happened, the index has closed the year on a positive note 29 times.
&#8220;This is yet another clue the lows are likely in and better times are coming,&#8221; Detrick wrote in an X post.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&gt;55% of the components in the S&amp;P 500 made a new 20-day high today. This is yet another clue the lows are likely in and better times are coming. Higher a year later 29 out of 30 times and up 16.3% on average. <a href="https://t.co/O0129ED0b9">pic.twitter.com/O0129ED0b9</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1922139786845831186?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The S&amp;P 500 index has a year-to-date performance low of 15.3%. Detrick highlighted that &#8220;Only three times in history has the S&amp;P 500 been down at least 15% YTD and moved back to positive by the end of the year.&#8221;
Despite having only three such instances historically, he added that 2025 could be the fourth such year.
&#8220;Call me crazy, but this year will be number four,&#8221; he said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Only three times in history has the S&amp;P 500 been down at least 15% YTD and moved back to positive by the end of the year. Call me crazy, but this year will be number four. <a href="https://t.co/JnVDNDgUKz">pic.twitter.com/JnVDNDgUKz</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1922131292151337121?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
After the 90-day tariff pause between the U.S. and China, John Murillo, chief dealing officer of B2BROKER, a global fintech solutions provider, said that the news triggered an immediate positive market response. 
"Stocks and oil prices have rebounded – apparently, in reaction to the news, which can lead to lower costs for businesses and consumers," Murillo noted.
Despite the initial positive action following the announcement, Murillo emphasized the <a href="https://www.benzinga.com/government/regulations/25/05/45367206/sp-500-rallies-over-3-on-us-china-90-day-tariff-truce-but-experts-warn-it-doesnt-guarantee-a-complete-resolution-of-the-trade-war">temporary nature of the agreement</a>. "Now, while the 90-day pause is a big step towards easing tensions, it&#8217;s crucial to remember that it doesn&#8217;t guarantee a complete resolution of the trade war."
Meanwhile, Ed Yardeni, the President of Yardeni Research, has <a href="https://www.benzinga.com/25/05/45367861/ed-yardeni-revises-recession-odds-to-25-after-the-rally-bumps-sp-500-year-end-target-to-6500">lowered his U.S. recession probability</a> to 25% while raising his S&amp;P 500 target to 6,500 points for this year, following the trade deal with China. &#8212;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul class="wp-block-list">
<li>April&#8217;s NFIB optimism index will be out by 6:00 a.m., whereas headline and core CPI data for April will be released by 8:30 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Under Armour Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) rose 1.45% in premarket on Tuesday as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of 8 cents per share on the revenue of $1.16 billion.</li>
</ul>
<ul class="wp-block-list">
<li>Cyberark Software Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) was up 0.94% as Wall Street expects it to report earnings of 79 cents per share on revenue of $305.23 billion before the opening bell.</li>
</ul>
<ul class="wp-block-list">
<li>JD.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) was 1% lower ahead of its earnings. Analysts expect earnings of $1.02 per share on revenue of $37.91 billion.</li>
</ul>
<ul class="wp-block-list">
<li>Acadia Healthcare Company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) jumped 4.99% after reporting better-than-expected first-quarter financial results after the closing bell on Monday. The company posted adjusted earnings of 40 cents per share, with revenue of $770.50 million.</li>
</ul>
<ul class="wp-block-list">
<li>Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) surged 8.98% after the announcement that the company will join the S&amp;P 500, effective before the opening of trading on Monday, May 19.</li>
</ul>
<ul class="wp-block-list">
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) dropped 31.51% after reporting a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.11.</li>
</ul>
<ul class="wp-block-list">
<li>Accelerate Diagnostics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) slumped 17.97% after it filed for Chapter 11 bankruptcy, leading to a delisting notice from Nasdaq due to non-compliance with listing requirements.</li>
</ul>
<ul class="wp-block-list">
<li>Microvision Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) tumbled 13.22% after reporting a 40% decline in first-quarter revenue, falling to $0.6 million.</li>
</ul>
<ul class="wp-block-list">
<li>OPTIMIZERx Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) zoomed 24.89% after it reported strong first-quarter financial results with revenue increasing 11% year-over-year to $21.9 million.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.45% to hover around $62.23 per barrel.
Gold Spot US Dollar rose 0.61% to hover around $3,254.39 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.18% at the 101.6080 level.
Asian markets ended on a mixed note on Tuesday as India's S&amp;P BSE Sensex and Hong Kong's Hang Seng index fell. While South Korea's Kospi, China&#8217;s CSI 300, Japan's Nikkei 225, and Australia's ASX 200 indices advanced. European markets were also mixed in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45368511/china-to-us-goods-shipment-jump-after-90-day-tariff-postponement-a-big-backlog-is-looming">China To US Goods Shipment Jump After 90-Day Tariff Postponement: &#8216;A Big Backlog Is Looming&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

General

$BTC

ACHC

COIN

CYBR

KDLY

MVIS

OPRX

US Stocks Likely To Open Lower After A Strong Rally: 'Lows Are Likely In And Better Times Are Coming,' Says Expert

Shares of Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) rose sharply in <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45365186/coinbase-stock-jumps-nearly-11-after-hours-monday-heres-why">today's pre-market trading</a>.
Coinbase is set to join the S&amp;P 500, replacing Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) in the benchmark index, according to a Monday announcement. The inclusion of Coinbase in the S&amp;P 500 will become effective before trading begins on May 19, according to a press release shared by S&amp;P Dow Jones Indices.
Coinbase shares jumped 9.2% to $226.29 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Lichen International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) rose 133.6% to $8.13 in pre-market trading after gaining 5% on Monday.</li>
<li>Inno Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INHD#NASDAQ">INHD</a>) surged 75.8% to $4.15 in pre-market trading. INNO HOLDINGS shares dipped 56% on Monday after the company announced a strategic cooperation with New Life Technology Development on developing a B2B marketplace platform.</li>
<li>Landsea Homes Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) gained 58.5% to $11.12 in pre-market trading after New Home Co. agreed to acquire the company for $11.30 per share in an all-cash transaction. Landsea Homes also reported a narrower-than-expected quarterly loss.</li>
<li>Crown LNG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) jumped 42.1% to $0.1706 in pre-market trading after gaining 5% on Monday.</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) gained 32.8% to $0.9701 in pre-market trading. The company recently posted downbeat quarterly results.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) surged 24.5% to $0.3102 in pre-market trading after gaining more than 43% on Monday.</li>
<li>Profound Medical Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROF#NASDAQ">PROF</a>) climbed 23.5% to $5.30 in pre-market trading. The company recently posted downbeat first-quarter results.</li>
<li>GigaCloud Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) gained 11.6% to $17.74 in pre-market after the company reported better-than-expected first-quarter financial results.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) gained 10% to $15.36 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares fell 92% to $0.0281 in pre-market trading. Polyrizon recently announced its planned reverse split will not be effected.</li>
<li>DevvStream Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEVS#NASDAQ">DEVS</a>) fell 48.8% to $0.67 in pre-market trading after jumping 290% on Monday.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) fell 32.3% to $0.5055 in today's pre-market trading following weaker-than-expected first-quarter results.</li>
<li>Kearny Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNY#NASDAQ">KRNY</a>) shares dipped 23.5% to $5.00 in pre-market trading after gaining 3% on Monday.</li>
<li>3D Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) shares fell 20.7% to $2.02 in pre-market trading after the company posted weaker-than-expected quarterly results.</li>
<li>Kindly MD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) dipped 18.2% to $11.15 in pre-market trading. KindlyMD shares jumped 251% on Monday after the company announced a merger agreement with Nakamoto Holdings to start a Bitcoin treasury strategy.</li>
<li>Accelerate Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) fell 18% to $0.11 in pre-market trading after dipping 9% on Monday. Accelerate Diagnostics recently announced it filed for Chapter 11 bankruptcy protection.</li>
<li>Klotho Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares tumbled 17% to $0.1448 in pre-market trading after gaining 5% on Monday.</li>
<li>Heritage Commerce Corp (NASDA: HTBK) declined 15.4% to $8.00 in pre-market trading.</li>
<li>Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) fell 12.1% to $10.15 in pre-market trading after the company reported mixed first-quarter financial results.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

ARWR

CGBS

DEVS

HTBK

INHD

KRNY

LICN

LSEA

PROF

RGTI

WLGS

Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 48.15 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $6.44 million which missed the analyst consensus estimate of $7.42 million by 13.21 percent. This is a 1.24K percent increase over sales of $481.00 thousand the same period last year.

Earnings Misses

Sangamo Therapeutics Q1 EPS $(0.14) Misses $(0.13) Estimate, Sales $6.44M Miss $7.42M Estimate

Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants to purchase 34,398,393 shares of its common stock, together with accompanying warrants to purchase 46,633,393 shares of its common stock. The combined offering price of each share of common stock and accompanying warrant is $0.50. The combined offering price of each pre-funded warrant and accompanying warrant is $0.49. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $0.75 per share, will become exercisable six months from the date of issuance and will expire six years from the date of issuance. All of the securities in the offering are to be sold by Sangamo. The offering is expected to close on or about May 14, 2025, subject to the satisfaction of customary closing conditions.
The gross proceeds to Sangamo from this underwritten offering, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $23.0 million. Sangamo intends to use the net proceeds from the offering for working capital and general corporate purposes.
Cantor is acting as sole book-running manager for the offering.

Offerings

Sangamo Therapeutics Prices $23M Underwritten Offering Of 12.235M Shares Of Common Stock And Pre-Funded Warrants At $0.50 And $0.49 Respectively, Including Accompanying Warrants Exercisable At $0.75

<h3>Gainers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock moved upwards by 28.6% to $0.94 during Monday's after-market session. The market value of their outstanding shares is at $48.6 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) shares rose 20.01% to $10.99. The market value of their outstanding shares is at $203.2 million. As per the press release, Q1 earnings came out today. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares moved upwards by 13.79% to $3.63. The company's market cap stands at $2.7 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares rose 10.28% to $0.34. The company's market cap stands at $21.1 million. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares increased by 10.13% to $0.39. The company's market cap stands at $17.1 million. As per the news, the Q1 earnings report came out today. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) shares increased by 9.09% to $0.36. The market value of their outstanding shares is at $17.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock declined by 88.0% to $0.04 during Monday's after-market session. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock decreased by 33.28% to $0.21. The company's market cap stands at $2.3 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares fell 26.13% to $0.31. The company's market cap stands at $1.4 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock declined by 25.43% to $0.1. The company's market cap stands at $2.5 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock fell 15.36% to $0.63. The company's market cap stands at $142.0 million. As per the news, the Q1 earnings report came out today. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares decreased by 10.06% to $0.16. The company's market cap stands at $4.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASBP

HBIO

HEPA

NIVF

PASG

12 Health Care Stocks Moving In Monday's After-Market Session

Sangamo Therapeutics Q1 GAAP EPS $(0.14) Misses $(0.13) Estimate, Sales $6.44M Miss $7.42M Estimate

ACHR

ACNT

AGEN

AIRJ

ALLT

ALTI

AMBC

AMPY

APEI

AQST

ASRT

ASYS

AUPH

BATRA

BATRK

Mobile Infrastructure Corporation Common Stock

BEEP

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLDE

BLNK

CATX

CEPU

CHGG

CLLS

CLPR

CMCL

CMPO

CNNE

CNTY

CPSS

CTMX

CTRI

CWCO

DOLE

EDIT

EXOD

FGEN

FOXA

FRPH

FTEK

FTRE

GAIA

GETY

GPRO

GRDN

HFFG

HNRG

IHRT

IMNN

INDI

ISPR

KBDC

KPTI

KSPI

LAND

LEGH

LINC

LTBR

METC

Ramaco Resources, Inc. - Class B Common Stock

METCB

MFIC

MLYS

MNDY

MODG

MRVI

MVST

NMRA

NOTE

NPWR

NRGV

NRXS

Earnings Scheduled For May 12, 2025

<ul>
<li>All dosed patients have passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway for ST-920.</li>
<li>According to preliminary analysis, mean estimated glomerular filtration rate (eGFR) slope at 52-weeks continued to remain positive.</li>
<li>Productive Type B Chemistry, Manufacturing and Controls (CMC) meeting with FDA provided clear CMC pathway to planned Biologics License Application (BLA) submission.</li>
<li>Pivotal data readout expected by end of second quarter of 2025.</li>
</ul>

Sangamo Therapeutics Announces Derisking Milestones For Pathway To Anticipated BLA Submission For ST-920 In Fabry Disease

Biotech

Events

Sangamo Therapeutics To Present At 28th Annual Meeting of the American Society of Gene & Cell Therapy May 13-17

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and maintains $10 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 80.6% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $9.6 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares rose 25.15% to $1.84. The market value of their outstanding shares is at $1.2 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) stock moved upwards by 23.77% to $0.54. The market value of their outstanding shares is at $2.5 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares moved upwards by 23.73% to $0.77. The market value of their outstanding shares is at $173.0 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares moved upwards by 14.89% to $1.08. The company's market cap stands at $14.7 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock moved upwards by 12.06% to $0.68. The company's market cap stands at $1.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) shares declined by 57.2% to $1.01 during Friday's pre-market session. The company's market cap stands at $46.4 million. </li>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) stock fell 41.28% to $0.51. The market value of their outstanding shares is at $15.5 million. </li>
<li>XOMA Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMAP#NASDAQ">XOMAP</a>) shares decreased by 35.09% to $16.71. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares declined by 30.39% to $1.26. The market value of their outstanding shares is at $16.7 million. </li>
<li>Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) shares decreased by 23.34% to $13.01. The company's market cap stands at $417.9 million. </li>
<li>Maze Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) stock fell 22.75% to $7.2. The market value of their outstanding shares is at $315.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

DNTH

KAPA

KRMD

MAZE

XOMAP

ZVSA

12 Health Care Stocks Moving In Friday's Pre-Market Session

U.S. stock futures declined on Friday after a bloodbath on Thursday following the introduction of President Donald Trump&#8216;s tariffs. Futures of major benchmark indices were lower in premarket trading.
Fueled by a broad market downturn, the Dow Jones plummeted by a staggering 1,679 points, its fifth-largest drop ever, while the S&amp;P 500 and Nasdaq suffered their biggest single-day losses since June and March 2020, respectively.
Trump, however, dismissed the tariff-induced selloff and said, &#8220;The market is going to boom, the stock is going to boom, the country is going to boom.&#8221;
The 10-year Treasury bond yielded 3.94% and the two-year bond was at 3.61%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a> shows markets pricing in a 69.4% likelihood of the Federal Reserve maintaining current interest rates through its May meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-1.00%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.78%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.54%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.42%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, declined in premarket on Friday. The SPY was down 0.71% to $532.87, while the QQQ declined 0.62% to $447.85, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Technology sectors bore the brunt of Thursday&#8217;s U.S. stock market downturn. Specifically, Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares plummeted approximately 9.3%, marking their steepest single-day decline since March 2020. Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) also saw a significant drop, tumbling 7.8%, while Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) shares fell by 8.98%. Across the broader market, consumer discretionary, energy, and information technology stocks registered the most substantial losses within the S&amp;P 500.
In contrast, consumer staples stocks stood out, bucking the prevailing negative trend and closing the session higher. This sector&#8217;s resilience was highlighted by Lamb Weston Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>), whose shares surged 10% after the company released third-quarter financial results that exceeded expectations and provided FY25 sales guidance above analyst estimates.
Economic data released Thursday presented a mixed picture. U.S. initial jobless claims decreased by 6,000 to 219,000 for the week ending March 29, falling below the anticipated 225,000. Additionally, the U.S. trade deficit narrowed to $122.7 billion in February, improving from $130.7 billion in January and slightly better than the forecasted $123.5 billion. However, the ISM services PMI declined to 50.8 in March, down from 53.5 in February and below market expectations of 53.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-5.97%</td>
<td>16,550.60</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-4.84%</td>
<td>5,396.52</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-3.98%</td>
<td>40,545.93</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-6.59%</td>
<td>1,910.55</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
CNBC&#8217;s Jim Cramer compared Trump&#8217;s tariffs to historical tariff regimes in the U.S., in an X post. he said, &#8220;It is not pro-tariff v. anti-tariff. It&#8217;s about accomplishing what&#8217;s good for our country while not having a Smoot-Hawley situation.&#8221;
The Smoot-Hawley Tariff Act, enacted in 1930, was a US law that significantly increased tariffs on imported goods, intended to protect American businesses and farmers, but ultimately worsened the Great Depression by triggering a global trade war.
However, he added that tariff-induced selloff on Thursday was &#8220;100% Smoot Hawley disguised as thoughtful policy. The market was RIGHT to go down.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It is not pro-tariff v. anti-tariff. It&#39;s about accomplishing what&#39;s good for our country while not having a Smoot Hawley situation. Yesterday was 100% Smoot Hawley disguised as thoughtful policy. The market was RIGHT to go down
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1908066366805991875?ref_src=twsrc%5Etfw">April 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
AQR Capital Management&#8217;s Chief Investment Officer, Cliff Asness, took to X on Thursday to voice his criticism of tariff proponents, specifically disputing the assertion that tariffs result in deflation instead of inflation.
His remarks were a direct response to Anthony Pompliano, the Founder &amp; CEO of Professional Capital Management and a well-known Bitcoin advocate, who had previously claimed, &#8220;Tariffs don't create inflation. The exact opposite happens."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Idiots say this and bray like they've scored a great point. What they mean is giant arbitrary tariffs are so bad they eventually cause recessions which then cause deflation. They then present this as a feature. And if they don't mean that they are even more wrong in some… <a href="https://t.co/ZihK0rbRU0">https://t.co/ZihK0rbRU0</a>
&mdash; Clifford Asness (@CliffordAsness) <a href="https://twitter.com/CliffordAsness/status/1907915579324760564?ref_src=twsrc%5Etfw">April 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Creative Planning&#8217;s chief market strategist, Charlie Bilello, noted that the VIX index reached its highest closing level since Aug. 5, 2024.
He suggested this increase in fear, coupled with lower stock prices, presents enhanced opportunities for investors with a long-term perspective. Bilello also pointed to historical trends, indicating that the S&amp;P 500 has historically delivered &#8220;higher than average&#8221; returns following significant surges in volatility.
He shared data showing that after a comparable spike on Aug. 5, 2024, the S&amp;P 500 returned 6% in one month, 11% in three months, and 18% over six months. On average, Bilello highlighted, the S&amp;P 500 has gained 12% six months after such volatility spikes and 21% after a year.
In an X post, Bilello summarized, &#8220;More Fear = More Opportunity.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The <a href="https://twitter.com/search?q=%24VIX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$VIX</a> spiked nearly 40% higher today and closed above 30 for the first time since last August. What has happened in the past following the biggest volatility spikes? Higher than average forward S&amp;P 500 returns. More Fear = More Opportunity<a href="https://t.co/wMMGtwYloS">https://t.co/wMMGtwYloS</a> <a href="https://t.co/vVEN5vUBD1">pic.twitter.com/vVEN5vUBD1</a>
&mdash; Charlie Bilello (@charliebilello) <a href="https://twitter.com/charliebilello/status/1907910013743722855?ref_src=twsrc%5Etfw">April 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Friday:
<ul>
<li>March&#8217;s U.S. employment report, unemployment rate, and hourly wages data will be out by 8:30 a.m. ET.</li>
</ul>
<ul>
<li>Fed Chairman Jerome Powell will speak at 11:25 a.m. ET.</li>
</ul>
<ul>
<li>Fed Governor Michael Barr will speak at 12:00 p.m. and Fed Governor Christopher Waller will speak at 12:45 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>American Shared Hospital Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMS#NYSE">AMS</a>) was up 0.34% in premarket on Friday ahead of its earnings before the opening bell. Analysts expect a quarterly earnings of 1 cent per share on revenue of $7.70 million.</li>
</ul>
<ul>
<li>Neuroone Medical Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) slumped 36.05% after the company disclosed a common stock public offering.</li>
</ul>
<ul>
<li>Simulations Plus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) was up 2.50% after posting stronger-than-expected results for its second quarter and issuing an upbeat FY25 earnings forecast.</li>
</ul>
<ul>
<li>Sangamo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) surged 32.41% after announcing a new agreement with pharmaceutical giant Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), granting the company a worldwide exclusive license to leverage the company&#8217;s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.</li>
</ul>
<ul>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) jumped 3.98% after its CEO, Ryan Cohen, acquired 500,000 shares of the company.</li>
</ul>
<ul>
<li>BioNexus Gene Lab Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) dropped 26.96% after the company said that it will enact a 1-for-10 reverse stock split effective Monday to meet Nasdaq&#8217;s bid price requirements.</li>
</ul>
<ul>
<li>Mullen Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) zoomed 83.64% after it stated that its U.S.-assembled Mullen and Bollinger commercial EV inventory is tariff-exempt.</li>
</ul>
<ul>
<li>CXApp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) gained 40.06% after the company reported business performance results for 2024 and announced a net revenue retention rate of 101%.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 3.57% to hover around $64.56 per barrel.
Gold Spot US Dollar declined 0.97% to hover around $3,083.92 per ounce. Its fresh record high stood at $3,168.04 per ounce. The U.S. Dollar Index spot was higher by 0.48% at the 102.564 level.
Asian markets closed on a lower note on Friday. India's S&amp;P BSE Sensex, Japan's Nikkei 225, Australia's ASX 200, China&#8217;s CSI 300, Hong Kong's Hang Seng, and South Korea's Kospi index fell. European markets were also lower in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/04/44642317/sp-500-plummets-108-nasdaq-100-corrects-141-since-trumps-inauguration-heres-how-it-compares-to-obama-and-biden-eras">S&amp;P 500 Plummets 10.8%, Nasdaq 100 Corrects 14.1% Since Trump&#8217;s Inauguration: Here&#8217;s How It Compares To Obama And Biden Eras</a></li>
</ul>
Photo courtesy: Shutterstock

Government

Market Summary

Futures

Commodities

Economics

Federal Reserve

Stocks Set To Continue Crashing After Worst Selloff Since 2020: Tariff Announcement Was '100% Smoot Hawley Disguised As Thoughtful Policy,' Says Expert

Comments

Sangamo Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL